Author: Jennifer Weiss-Wolf

Jennifer Weiss-Wolf is the executive director of Ms. partnerships and strategy. A lawyer, fierce advocate and frequent writer on issues of gender, feminism and politics in America, Weiss-Wolf has been dubbed the “architect of the U.S. campaign to squash the tampon tax” by Newsweek. She is the author of Periods Gone Public: Taking a Stand for Menstrual Equity, which was lauded by Gloria Steinem as “the beginning of liberation for us all,” and A Citizen’s Guide to Menopause Advocacy, together with Dr. Mary Claire Haver (featuring a foreword by Maria Shriver). Her forthcoming book When in Menopause: A User’s Manual and Citizen’s Guide (Hachette US-Sheldon Press) will be published in Fall 2026. She is also the executive director of the Birnbaum Women’s Leadership Center at NYU Law. Find her on Twitter: @jweisswolf.

Whose America Turns 250? Democracy Is Still a Feminist Fight

As the United States approaches its 250th anniversary, we face a fundamental question: Whose America are we celebrating?

From the unfinished promise of the Equal Rights Amendment, to the fall of Roe v. Wade, the story of American democracy has always been intertwined with the struggle for women’s equality.

Women—especially Black women—have long been among democracy’s most engaged participants, yet the institutions meant to represent the people continue to fall short of reflecting the nation’s diversity, needs and aspirations.

The erosion of reproductive freedom, voting rights and representative government are not separate crises; they are connected symptoms of a democracy that remains incomplete. Anti-democratic forces have repeatedly overridden popular will, making it harder to achieve broadly supported policies that would improve the lives of women and families. The fight for gender equality, bodily autonomy and political power is inseparable from the fight to build a democracy that truly works for everyone.

That conviction is at the heart of FEMINIST 250: Democracy’s Feminist Future, which begins at Ms. Thursday, June 18.

Through essays from leading advocates, organizers and thinkers—including LaTosha Brown, Skye Perryman, Reshma Saujani and Inimai Chettiar—the series offers bold ideas for strengthening democratic institutions, advancing equality and creating a more inclusive future.

Taken together, these essays remind us that democracy remains a feminist project—and that the next chapter of the American experiment is still ours to write.

America’s Medical Research System Has Been Failing Women for Generations

and

For decades, women have been systematically excluded, overlooked and underfunded by America’s scientific and medical institutions—and the consequences are measurable. Women were not required to be included in federally funded clinical research until 1993, and even today, no more than 8.8 percent of NIH grant spending goes toward women’s health research. The result is a dangerous knowledge gap that affects everything from cardiovascular disease and autoimmune disorders to drug safety, maternal health and reproductive care.

The problem transcends partisan politics. While the Trump administration’s cuts to women’s health research have intensified concerns, Democratic and Republican administrations alike have failed to prioritize women’s health.

Private philanthropy and venture capital have also fallen short, with women’s health receiving just a fraction of available funding.

As women face rising healthcare deserts, worsening maternal mortality rates and persistent gaps in diagnosis and treatment, meaningful progress will require action on every front—from federal investment and philanthropy to innovative new funding models focused specifically on women’s health research.

Of Course Trump Is Going After E. Jean Carroll

Last week, multiple outlets reported that the Justice Department would be opening a criminal investigation into E. Jean Carroll, the 82-year-old iconic journalist who successfully sued Donald Trump—twice.

It has been more than two years since she prevailed in back-to-back civil lawsuits against him, winning a $5 million verdict in May 2023, followed by another $83.3 million in January 2024. The first jury found Trump liable for committing sexual abuse in a department store dressing room in 1996, as well as defamation for saying Carroll lied about it. The second case, brought because he just wouldn’t stop with the defamation, multiplied the damages exponentially.

The timing of the DOJ announcement should come as no surprise, at least from a public relations point of view. Ask E. Jean, the new documentary about Carroll’s life, including the court cases, premiered days prior. After debuting at the Telluride Film Festival last year without much fanfare, the film is now selling out theaters, garnering high-profile coverage and reviews, and likely embarrassing the president even more than his colossal legal defeat.

Meanwhile, among legal analysts, there is widespread agreement that the DOJ has no legitimate basis for investigating Carroll. But that is hardly the point when it comes to this administration, especially the weaponization of the Justice Department now led by acting Attorney General Todd Blanche, who represented Trump personally in the Carroll case (and supposedly is recused from this investigation).

Three Ways Trump’s Weird Fixation on DEI Is Hurting Women

The Trump administration’s obsession with diversity, equity and inclusion has moved far beyond rhetoric. It is now reshaping how women’s stories get told, whose health crises are allowed to be named, and what kinds of research are permitted to survive.

Across history, healthcare and science, women are watching decades of hard-fought progress become collateral damage in a culture war designed to erase people in real time.

That damage is already visible.

Republicans derailed long-awaited progress on the American Women’s History Museum by inserting provisions policing which women count as women and handing Trump appointees sweeping control over the museum itself.

Meanwhile, the newly reintroduced Momnibus legislation—created in response to the maternal mortality crisis devastating Black women and families—has been forced to strip much of the word “Black” from its language in order to survive politically under an administration openly hostile to DEI initiatives.

And the consequences are not abstract: NIH grants focused on women’s health have reportedly dropped by 30 percent, while words like “women” and “gender” themselves are becoming liabilities in funding proposals.

Women’s health was already chronically underfunded and misunderstood long before Trump returned to office. But the administration’s escalating war on DEI is accelerating that neglect—and making clear just how much is at stake when political ideology begins dictating whose lives deserve to be studied, protected and remembered.

Women’s Health Is a Democracy Issue—and a Midterm One

It is critically important to keep reproductive health and the chaos at the Food and Drug Administration (FDA) front and center in the headlines. Why? Two words: midterm elections.

Last week, within 48 hours of each other the Supreme Court issued an emergency stay pausing the Fifth Circuit’s attempt to let Louisiana negate the FDA rule that allows telehealth provision and mail delivery of mifepristone, and FDA commissioner Marty Makary announced his immediate resignation after rumors that President Trump was planning to fire him.

Though Makary’s antipathy toward deregulation of flavored vapes appears to have triggered his fall from grace, and the rest of the chaos is perhaps business as usual, the Trump administration’s tip-toe approach to mifepristone is the real story.

The Justice Department’s litigation approach seemingly has been to wait until October when the FDA’s so-called “safety review” is due—ordered despite the mountain of evidence proving mifepristone’s safety and efficacy. But reports indicate that study has not even begun and is mired in data delays caused by the Department of Health and Human Services.

Foot-dragging? Finger-pointing? Old-fashioned incompetence? Who can tell anymore. But it surely hews to Republicans’ favor to keep the entire endeavor out of public sight, given that the vast majority (68 percent) of adults in this country oppose banning mifepristone.

A Government for Big Tobacco and Bigger Families

The Department of Health and Human Services (HHS) made multiple headlines last week—starting with the apparent implosion of Dr. Marty Makary’s tenure as Food and Drug Administration commissioner. But beneath the chaos lies something more troubling: a federal health apparatus increasingly shaped by antiabortion pressure campaigns, pronatalist messaging and culture-war governance masquerading as public policy.

From the Supreme Court fight over mifepristone access to the Trump administration’s bizarre new moms.gov initiative—complete with links to antiabortion crisis pregnancy centers and rhetoric about Americans being “under-babied”—the week offered a revealing snapshot of where U.S. health policy is headed. Meanwhile, flavored vape approvals for Big Tobacco sailed through the FDA, even as reproductive healthcare access remains under constant attack.

Chaos may be Trump’s currency, but the throughline here is ideology: rewarding conservative allies, policing reproductive autonomy and repackaging motherhood as a nationalist project while offering little meaningful material support to actual families.

The Fifth Circuit Proves Abortion Is on the Ballot this November

A highlight of being in Ireland has been following the local news, especially the robust abortion beat: Irish lawmakers have been waging a loud fight to expand abortion rights—in particular, to ensure unnecessary waiting periods don’t impede access to care.

Breaking headlines from the United States were a dark juxtaposition.

The U.S. is one of only four nations worldwide actively rolling back reproductive rights.

And now we’re threatened with yet another fight: The Fifth Circuit Court of Appeals issued a ruling late last week aiming to create the most significant setback to abortion access since the Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision four years ago.

The three-member panel, two of whom are Trump appointees, blocked a 2023 FDA policy allowing mifepristone to be prescribed by telehealth providers and delivered by mail—a decision that applies to all states, whether abortion is legal or not, and where voters have mobilized to pass ballot measures and enshrine reproductive rights in their state constitutions.

This Fifth Circuit ruling is not the final word on the case. The two pharmaceutical companies that make mifepristone, Danco and GenBioPro, immediately filed an emergency appeal to the Supreme Court. On Monday, Justice Samuel Alito announced an administrative stay through May 11, meaning the decision is on hold until at least then, while the justices review the appeal and decide whether the medically unnecessary in-person dispensing requirements can be reimposed for the duration of the litigation.

In the spirit of the fighting Irish, readers should take heart that the community of U.S. abortion providers, advocates and support networks “have shown amazing resilience and tenacity since the Dobbs decision,” according to Kelly Baden of Guttmacher. “They will continue to do what they can do to ensure that everyone, regardless of where they live, can access the abortion care they need.”

So, for now, our citizen mobilization strategy must be twofold: Support those who directly deliver those services and get ready to get loud. The abortion fight shows that access to healthcare, the integrity of science, the rules of democracy, and the right to bodily autonomy are not only all interconnected, but they are all on the ballot this November.

The Gun Crisis Is a Maternal Health Crisis. Virginia Shows What a Comprehensive Response Looks Like.

When the shots rang out at the Washington Hilton, it had not even been a week since the nation mourned the eight children shot dead in Shreveport, La., seven of whom were the gunman’s own. Two women, including his wife, were also shot but survived; another child jumped off a roof to escape the shooting.

More than just about anywhere else in the country, American classrooms have become ground zero for preparing kids. That was the first thought I had when I heard real-time Saturday night dispatches, reporters claiming they instinctually knew to crouch under tables. That’s not instinct. That is an entire generation raised on active-shooter drills. (I’ll never forget my then 8-year-old daughter nonchalantly explaining to me the difference between color-coded school drills. “Don’t be silly, Mom, no one has to go in the closet for a Code Yellow.”)

Not surprisingly, mothers have taken up the mantle.

Over the past week, a suite of gun safety bills headed to Gov. Abigail Spanberger’s desk, several of which she signed into law, and others she amended, including a ban on the sale of assault weapons and high-capacity magazines—Virginia would be the 11th state to enact such a ban—as well as protections for domestic violence survivors, age limits on gun purchases, safe storage requirements and industry accountability measures.

She simultaneously signed bipartisan legislation known as the Momnibus, which aims to improve and expand healthcare coverage for mothers and families, particularly women who face the highest risks, by codifying the need to collect maternal health data, supporting mental health screenings of new parents, and expanding insurance and Medicaid coverage for a variety of care.

Paid family and medical leave is the third key advance, which Spanberger signed into law last week as well.

As we look ahead to the midterm elections, remember there are indeed policies that can make us safer and healthier. Don’t let anyone in the political establishment convince us it is not so.

From Pennsylvania to Illinois to California: A Wave of Good News for Women

It is a relief to point to bona fide good news coming from the states, often some of the best laboratories for democracy.

In Pennsylvania, an appeals court struck down a decades-old law banning the use of state Medicaid funding to cover abortion. Truly remarkable is the majority’s decree that reproductive autonomy is enshrined in the equal protection provision of the Pennsylvania Constitution, guaranteed under its Equal Rights Amendment. ERAs can be game-changing for bolstering legal protection against a wide array of discrimination—including on the basis of pregnancy, age, disability, and immigration status—as well as for addressing adjacent issues such as pay equity and transparency and gender-based violence.

Upcoming judicial elections in Georgia are fast becoming a reproductive rights referendum, as happened last year in Wisconsin. Activists are raising funds in force. 

Idaho voters will likely get to weigh in directly on abortion rights in the November midterms.

… and more.

Fewer Teen Births Is Good, Unless You’re the Patriarchy

How on-brand for the federal government to announce that U.S. birth rates are falling—just as The Testaments, the long-awaited sequel to The Handmaid’s Tale, dropped on Hulu.

In the fictional nation of Gilead, first envisioned by Margaret Atwood in her 1985 dystopian novel and expanded on screen for nearly a decade now, declining fertility catalyzed a Christian nationalist revolution in modern-day America, spawning a society rooted in patriarchal dominance and state-sanctioned violence. The Testaments, now three episodes in, is making a deliberate appeal to Gen Z and young viewers, featuring the spectacularly savvy Chase Infiniti and Lucy Halliday among Gilead’s tradwife-in-training rebels.

Doubly fascinating then, that it is the real-life status of teen birth rates in particular now driving the news. In a drop considered “extraordinary” by statisticians, the number of babies born to mothers between the ages of 15 and 19 fell by 7 percent in 2025.

Nevertheless, many on the right jumped directly into the fray to publicly lament that teens are having fewer babies.